Search results for "Central obesity"

showing 10 items of 10 documents

Hemostatic function in young subjects with central obesity: relationship with left ventricular function.

1995

This study was designed to evaluate coagulation and fibrinolysis activity and their relationship with left ventricular function in young obese subjects with central fat distribution. We assessed coagulation and fibrinolysis activity by evaluation of factor VII activity, fibrinogen and plasminogen, plasminogen activator inhibitor (PAI), and tissue plasminogen activator antigen basally (tPA1) and after venous occlusion (tPA2). These measures were evaluated in young (< 40 years) obese subjects with central fat distribution (n = 19) and in comparable lean subjects (n = 20). Blood glucose, triglycerides, total and high-density lipoprotein (HDL) cholesterol, apolipoprotein (apo) A1 and apo B, fas…

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenVentricular Function LeftSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundEndocrinologyWaist–hip ratioInternal medicineFibrinolysismedicineHumansInsulinObesityHemostatic functionBlood CoagulationApolipoproteins ATriglyceridesApolipoproteins BHemostasisbiologybusiness.industryCholesterolCholesterol HDLFibrinogenCentral obesity Hemostatic function left ventricular functionPlasminogenFactor VIISettore MED/11 - Malattie Dell'Apparato CardiovascolarePlasminogen InactivatorsEndocrinologychemistrybiology.proteinBody ConstitutionRegression AnalysisFemalebusinessPlasminogen activatormedicine.drugLipoproteinMetabolism: clinical and experimental
researchProduct

Central obesity and hypertension. Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subj…

1994

This study was designed to evaluate the role of fasting serum insulin and plasma renin activity in obesity-induced hypertension. In view of this, plasma catecholamines, fasting serum insulin (IRI), urinary sodium excretion (NaU), plasma renin activity (PRA), and plasma aldosterone (PA) levels were assessed in young (age less than 40 years) normotensive (n = 27) and hypertensive (n = 14) subjects with central obesity and in lean normotensives (n = 20). Central obesity was evaluated by waist-to-hip ratio (WHR) according to the indication of the Italian Consensus Conference of Obesity. PRA, PA, IRI, and plasma norepinephrine levels were significantly (P < .05) higher in both obese groups than …

AdultMalemedicine.medical_specialtyCentral obesityHypertension Insulin Renin-angiotensin-aldosterone systemSettore MED/09 - Medicina Internamedicine.medical_treatmentBlood Pressureurologic and male genital diseasesPlasma renin activitySettore MED/13 - Endocrinologiachemistry.chemical_compoundDiastoleReference ValuesInternal medicineRenin–angiotensin systemBlood plasmaReninInternal MedicinemedicineHumansInsulinObesityAldosteronebusiness.industryInsulinFastingmedicine.diseaseObesitySettore MED/11 - Malattie Dell'Apparato Cardiovascolarefemale genital diseases and pregnancy complicationsEndocrinologyBlood pressurechemistryHypertensionFemalebusinessBody mass index
researchProduct

Lymphocyte beta-adrenergic receptors in young subjects with peripheral or central obesity: relationship with central haemodynamics and left ventricul…

1994

This study was designed to evaluate total (t) and surface (s) β-adrenergic receptor (BAR) density and their relationship with central haemodynamics and left ventricular function in young subjects with central or peripheral obesity. A total of 31 obese subjects (BMI ≥30.5 kg. m−2 for males and >27.3 kg. m−2 for females) aged less than 40 years and without other risk factors for cardiovascular diseases (smoking, hypertension, diabetes and lipid abnormalities) were studied. Nine had peripheral obesity and 22 central obesity according to WHR values; there were 20 lean controls (BMI <25 kg. m−2 for males and <24.7 kg. m−2 for females). Casual (c) and 24 h ambulatory mean blood pressures (MBP-24 …

AdultMalemedicine.medical_specialtyCardiac outputSettore MED/09 - Medicina InternaMegalencephalic leukoencephalopathy with subcortical cystsEpinephrineDiastoleHemodynamicsBlood volumeVentricular Function LeftBody Mass IndexNorepinephrineRisk FactorsInternal medicineDiabetes mellitusReceptors Adrenergic betamedicineHumansInsulinLymphocytesObesitySystoleRadionuclide ImagingEjection fractionbusiness.industryHemodynamicsHeartmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologyCardiovascular DiseasesEchocardiographyBody ConstitutionRegression AnalysisPeripheral obesity Central Obesity Lymphocyte beta adrenergic receptors left ventricular functionFemaleCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

FRI0349 PSORIATIC ARTHRITIS AND CENTRAL OBESITY: STRONG ASSOCIATION WITH FUNCTIONAL DISABILITY AND A WORSE QUALITY OF LIFE

2020

Background:Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with comorbidities like obesity, metabolic syndrome, and cardiovascular disease. Adipose tissue leads to a pro-inflammatory status in obese subjects. For this reason, central obesity may determine a worsening in both disability index or quality of life in PsA patients treated with biologic agents.Objectives:Our study aimed to evaluate the relationship between central obesity and disability index or the impact of the disease on quality of life in a real-world sample of PsA patients.Methods:A cross-sectional study was conducted. Patients with PsA were enrolled at the PsA clinic at the ARNAS Civico in Palermo (…

030203 arthritis & rheumatology0301 basic medicinemedicine.medical_specialtypsoriatic arthriticentral obesitybusiness.industryInflammatory arthritisImmunologyArthritismedicine.diseaseGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesPsoriatic arthritis030104 developmental biology0302 clinical medicineRheumatologyQuality of lifeInternal medicineRheumatoid arthritisDiabetes mellitusmedicineImmunology and AllergyFunctional abilityMetabolic syndromebusinessAnnals of the Rheumatic Diseases
researchProduct

Change in weight and central obesity by positive airway pressure treatment in obstructive sleep apnea patients: longitudinal data from the ESADA coho…

2018

The effect of positive airway pressure treatment on weight and markers of central obesity in patients with obstructive sleep apnea remains unclear. We studied the change in body weight and anthropometric measures following positive airway pressure treatment in a large clinical cohort. Patients with obstructive sleep apnea with positive airway pressure treatment from the European Sleep Apnea Database registry (n = 1, 415, 77% male, age 54 ± 11 [mean ± SD] years, body mass index 31.7 ± 6.4 kg/m2, apnea–hypopnea index 37 ± 24 n per hr, Epworth Sleepiness Scale 10.2 ± 5.0) were selected. Changes in body mass index and neck/waist/hip circumferences at baseline and at follow-up visit were analyse…

Data AnalysisMaleTime FactorsExcessive daytime sleepinessWeight Gainexcessive daytime sleepineBody Mass IndexCohort StudiesBehavioral Neuroscience0302 clinical medicinePositive airway pressureMedicineLongitudinal StudiesProspective Studiesobstructive sleep apneaSleep Apnea ObstructiveContinuous Positive Airway PressureEpworth Sleepiness ScaleSleep apneaGeneral MedicineMiddle Agedweight ; central obesity ; positive airway pressure ; obstructive sleep apnea ; ESADA cohortEuropeObesity AbdominalCardiologyFemaleWaist Circumferencemedicine.symptomAdultmedicine.medical_specialtyCognitive NeuroscienceSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicineHumanspositive airway pressureAgedcentral obesitybusiness.industryBody Weightbody weight central obesity excessive daytime sleepiness obstructive sleep apnea positive airway pressureta3121medicine.diseaseObesityrespiratory tract diseasesObstructive sleep apnea030228 respiratory systemHuman medicinebusinessBody mass indexWeight gain030217 neurology & neurosurgery
researchProduct

Relationship between clinical variables and Patient-Reported Outcomes in patients with psoriatic disease

2021

Background Psoriatic Arthritis (PsA) is a chronic inflammatory form of Arthritis associated with enthesitis, dactylitis, nail dystrophy, uveitis, and osteitis. PsA is strongly associated with comorbidities such as obesity, metabolic syndrome, and cardiovascular disease. As usual PsA patients are assessed either by rheumatologist or dermatologist but a multiprofessional assessment for those subjects is important to improve their disease control and their quality-of-life. The multidimensional assessment is a new model of care for PsA patients in which a multiprofessional team (rheumatologist, dermatologist, internal medicine physician, nutritionist and a phycologist) with a nurse as case mana…

Quality-of-lifeNursingPsoriatic ArthritiCentral ObesityPatient-Reported-OutcomeSettore MED/45 - Scienze Infermieristiche Generali Cliniche E Pediatriche
researchProduct

Association between reduced lymphocyte beta-adrenergic receptors and left ventricular dysfunction in young obese subjects

1994

This study was designed to evaluate total (t) and surface (s) beta-adrenergic receptors (BAR) density and their relationships with left ventricular function in young obese subjects. BAR density, plasma insulin, catecholamines and left ventricular function were evaluated in 27 young obese subjects (BMI30.5 kg/m2 for males and27.3 kg/m2 for females) without other risk factors for cardiovascular diseases (smoking, hypertension, diabetes and lipid abnormalities) and in 20 lean controls (BMI25 kg/m2 for males and24.7 kg/m2 for females). Both groups were matched for gender, age and body height. BAR density was evaluated according to Böyum and De Blasi methods. Plasma catecholamines by high perfus…

AdultMaleAgingSettore MED/09 - Medicina InternaRadioimmunoassayPeripheral obesity Central Obesity lymphocyte beta adrenergic receptors left ventricular functionStroke VolumeSettore MED/11 - Malattie Dell'Apparato CardiovascolareVentricular Function LeftCatecholaminesEchocardiographyReceptors Adrenergic betaHumansInsulinRegression AnalysisFemaleLymphocytesObesityCardiac OutputRadionuclide AngiographyChromatography High Pressure Liquid
researchProduct

Differences in cardiometabolic risk profiles between Chinese and Finnish older adults with glucose impairment and central obesity.

2022

Abstract Background Obesity and ethnicity play important roles in cardiovascular complications in patients with type 2 diabetes mellitus (T2DM). This study aimed to compare cardiometabolic risk profiles between Chinese and Finnish older adults of central obesity with prediabetes or T2DM. Methods Study subjects were 60–74 years old and originated from two population samples. The Finnish subjects came from the Kuopio Ischemic Heart Disease (KIHD) study (n = 1089), and the Chinese subjects came from the Shanghai High-risk Diabetic Screen (SHiDS) study (n = 818). The KIHD and SHiDS studies used similar questionnaires to determine participants’ baseline characteristics regarding the history of m…

GerontologyBlood GlucoseChinaEndocrinology Diabetes and MetabolismEndocrinology and DiabetesPrediabetic StateEndocrinologyRisk FactorsType 2 diabetes mellitusEthnicitymedicineHumanssuomalaisetObesityFinlandTriglyceridesAgedCardiometabolic riskChinesebusiness.industryFinnishCholesterol HDLriskitekijätMiddle AgedkiinalaisetCardiovascular disease riskmedicine.diseaseObesityGlucoseDiabetes Mellitus Type 2Cardiovascular DiseasesCentral obesityObesity AbdominalEndokrinologi och diabetessydän- ja verisuonitauditlihavuusInsulin Resistancebusinessaikuistyypin diabetesJournal of endocrinological investigation
researchProduct

Central obesity and hypertensive renal disease: association between higher levels of BMI, circulating transforming growth factor beta1 and urinary al…

2004

OBJECTIVE: In this study, the relationship between circulating transforming growth factor beta1 (TGFbeta1) and urinary albumin excretion (UAE) has been investigated in non-obese and central obese hypertensive patients. DESIGN AND PATIENTS: Fifty-eight consecutive hypertensive outpatients both lean and with central obesity were enrolled and divided in three groups, according to their body mass index (BMI) values. Group A: 16 lean hypertensives (men with BMI or = 25 kg/m2 and 24.7 kg/m2 and or = 30 kg/m2 and women with BMI > or = 27.3 kg/m2). MEASURES: In all patients, UAE, by immunonephelometric assay, circulating TGFbeta1 by a solid-phase specific sandwich enzyme-linked immunosorbent assay …

AdultMalemedicine.medical_specialtyHypertension RenalSettore MED/09 - Medicina Internacentral obesity hypertension transforming growth factor beta1 urinary albumin excretionOverweightBody Mass IndexExcretionTransforming Growth Factor beta1chemistry.chemical_compoundElectrocardiographyTransforming Growth Factor betaInternal medicineInternal MedicineMedicineAlbuminuriaHumansObesityBlood urea nitrogenAgedSettore MED/14 - NefrologiaCreatininebusiness.industryBody Weightnutritional and metabolic diseasesGeneral MedicineMiddle Agedmedicine.diseaseObesitySettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheEndocrinologychemistryHeart Function TestsAlbuminuriaRegression AnalysisFemaleKidney Diseasesmedicine.symptomCardiology and Cardiovascular MedicinebusinessBody mass indexKidney disease
researchProduct

Models for non-alcoholic fatty liver disease: a link with vascular risk.

2008

Non alcoholic fatty liver disease (NAFLD) is often part of the metabolic syndrome which includes central obesity, dyslipidaemia, insulin resistance/type 2 diabetes mellitus and hypertension. In turn, NAFLD may be associated with an increased vascular risk. Several experimental models which express histological steatosis or steatohepatitis with fibrosis have been described. This review identifies those models of NAFLD with features of vascular risk.

medicine.medical_specialtyDiseasedigestive systemGastroenterologyInsulin resistanceNAFLD central obesity dyslipidaemia insulin resistance/type 2Risk FactorsInternal medicineDrug DiscoveryAnimalsHumansMedicineVascular DiseasesRisk factorPharmacologybusiness.industryFatty livernutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseasedigestive system diseasesFatty LiverDisease Models AnimalEndocrinologyInflammation MediatorsSteatosisMetabolic syndromeSteatohepatitisbusiness
researchProduct